Objective To analyze the application value of Bevacizumab for the treatment of advanced non-small cell lung cancer(NSCLC)with epidermal growth factor receptor(EGFR)-sensitive mutations.Methods Ninety-one patients with advanced NSCLC with EGFR-sensitive mutations originating from Affiliated Hospital of Guilin Medical College from October 2021 to July 2023 were selected and divided into reference group and study group according to the randomized numerical table method,the reference group(n=45)implemented treatment with Alectinib,and the study group(n=46)carried out treatment with Alectinib combined with Bevacizumab.The clinical efficacy,serum carcinoembryonic antigen(CEA),cytokeratin 19 fragment antigen 21-1(CYFRA21-1),glycoconjugate antigen 153(CA153),serum immunoglobulin A(IgA),immunoglobulin M(IgM),and immunoglobulin G(IgG)indexes of the two groups were compared.Results The objective remission rate of the study group was higher than that of the reference group,and the difference was statistically significant(P＜0.05).The indexes of CEA,CYFRA21-1 and CA153 in the study group after treatment were lower than those in the reference group,and the indexes of CEA,CYFRA21-1 and CA153 in the two groups after treatment were lower than those before treatment,with statistical significances(P＜0.05).The IgA,IgM and IgG indexes of the study group after treatment were higher than those of the reference group,and the IgA,IgM and IgG indexes of the two groups after treatment were lower than those before treatment,with statistical significances(P＜0.05).Conclusion The effect of Alectinib combined with Bevacizumab in the treatment of advanced NSCLC with EGFR-sensitive mutations is remarkable,which can effectively improve the clinical treatment efficiency,control the tumor growth,and improve the immune function of the body,so it is worthwhile to be clinically applied and promoted.
关键词
贝伐珠单抗/阿美替尼/表皮生长因子受体/非小细胞肺癌
Key words
Bevacizumab/Alectinib/Epidermal growth factor receptor/Non-small cell lung cancer
维普
万方数据